Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -$561.10M. The highest annual figure on record is $14.73B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$561.10M | – |
| FY2024 | Dec 31, 2024 | -$152.85M | – |
| FY2023 | Dec 31, 2023 | -$17.52M | – |
| FY2022 | Dec 31, 2022 | -$1.11B | -107.6% |
| FY2021 | Dec 31, 2021 | $14.73B | +2972.7% |
| FY2020 | Dec 31, 2020 | $479.31M | +1585.0% |
| FY2019 | Dec 31, 2019 | $28.45M | +1120.9% |
| FY2018 | Dec 31, 2018 | $2.33M | -95.1% |
| FY2017 | Dec 31, 2017 | $47.84M | – |
| FY2016 | Dec 31, 2016 | -$26.56M | – |
| FY2015 | Dec 31, 2015 | -$1.09M | – |
| FY2014 | Dec 31, 2014 | -$21.04M | -4849.4% |
| FY2013 | Dec 31, 2013 | $443.00K | – |
| FY2012 | Dec 31, 2012 | -$32.41M | – |
| FY2011 | Dec 31, 2011 | -$1.52M | – |
| FY2010 | Dec 31, 2010 | -$39.10M | -188.7% |
| FY2009 | Dec 31, 2009 | $44.09M | – |
See a number that looks wrong?